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Pooled peptides from HER-2/neu-overexpressing primary ovarian
tumours induce CTL with potent antitumour responses in vitro
and in vivo
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Unfractionated peptides (MW: up to 10kDa), derived from HLA-A2.1 positive (þ) HER-2/neu-overexpressing primary tumour cell
acid cell extracts (ACE), were successfully used to generate in vitro cytotoxic T lymphocytes (CTL). Primary tumour cells were
collected from peritoneal malignant effusions of patients with ovarian cancer. Acid cell extracts-induced CTL specifically lysed in an
HLA-A2-restricted manner HER-2/neu
þ autologous primary tumour cells as well as HER-2/neu
þ tumour cell lines. In addition,
adoptive transfer of such CTL significantly prolonged the survival of SCID mice xenografted with HLA-A2.1
þ, HER-2/neu
þ human
breast and ovarian tumour cell lines. Acid cell extracts collected from HLA-A2.1
þ HER-2/neu negative ( ) primary ovarian tumours
induced HLA-A2.1-restricted CTL with weak in vitro and in vivo antitumour capacity, suggesting that HER-2/neu peptides within ACE
from HER-2/neu-overexpressing primary ovarian tumour cells are immunodominant. The results presented herein serve as a
rationale for the initiation of vaccination studies in patients with HER-2/neu-overexpressing ovarian tumours utilising autologous
tumour-derived ACE.
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It is now well established that tumours growing in vivo provide
their antigens to the immune system either as soluble proteins by
shedding from the surface of viable cells or as ‘apoptotic bodies’
from dead cells. Tumour antigens, during the process of ‘cross-
priming’ are taken up by antigen-presenting cells (APC) which
present them to cytotoxic T lymphocytes (CTL), thereby eliciting
the induction of antitumour immune responses (Carbone et al,
1998). A significant number of tumour antigens, which function as
CTL targets, have now been identified using various approaches
including molecular genetic techniques, immunoaffinity purifica-
tion of MHC molecules followed by acid elution of peptides and
subsequent sequence determination, serological analysis of re-
combinant cDNA expression libraries, and identification of
peptide sequences with MHC class I-binding motifs through
computer algorithms (Wang and Rosenberg, 1999).
The use of defined tumour antigens in peptide-based vaccina-
tion studies for cancer immunotherapy is advantageous because it
provides pure antigenic preparation that enhances the effective-
ness of the vaccine and at the same time minimises the possibility
of adverse autoimmune reactions due to the absence of irrelevant
material such as self-proteins shared between tumour cells and
healthy tissue. However, the use of defined CTL epitopes in
peptide-based vaccines provides several obstacles to effective
cancer immunotherapy. Firstly, it is not always certain that a
tumour epitope eliciting CTL responses in vitro can also be
recognised by CTL in vivo, thereby eliciting antitumour responses
(Anichini et al, 1996; Kirkin et al, 1999). Secondly, tumour
peptide-specific CTL efficiently recognising peptide-pulsed target
cells do not necessarily recognise tumour cells presenting naturally
processed epitopes (Van Elsas et al, 1995; Zaks and Rosenberg,
1998). Finally, peptide-based vaccinations may induce the genera-
tion of tumour escape variants lacking the expression of a
particular peptide epitope (Pawelec, 1999).
An alternative approach that circumvents these problems is the
use of unfractionated peptides, as a source of tumour antigens,
isolated from tumour cell lysates produced upon acid treatment
(ACE) (Nair et al, 1997). The presence of multiple peptides within
ACE may ensure the induction of several peptide-specific CTL
clones of different affinities for a given peptide which will
synergistically mount an effective antitumour response. The
existence of a plethora of tumour peptide-specific CTL clones will
reduce the risk of generation of tumour escape variants since
tumour cells will be attacked via the recognition of multiple
antigens restricted by several HLA alleles (Pawelec, 1999). In
addition, peptide mixtures present within ACE circumvent the
need for characterising tumour-specific antigens and open the
possibility for vaccination protocols in cases where tumour
antigens have not been identified. Simultaneous presentation of
CTL and TH epitopes by dendritic cells (DC) may be highly
increased when tumour lysates are used as sources of antigenic
material (Baxevanis et al, 2000).
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lysates as tumour vaccines has been explored in preclinical studies
(Nair et al, 1997; Fields et al, 1998; Gatza and Okada, 2002; Schnurr
et al, 2002; Wen et al, 2002; Gad et al, 2003; Graner et al, 2003;
Vegh and Mazumder, 2003) as well as in clinical trials for the
immunotherapy of melanoma (Nestle et al, 1998) and renal cell
carcinoma (Holth et al, 2002). Their majority of these experi-
mentations included DC as the preferred APC. Given the technical
difficulties in obtaining high numbers of pure mature DC from
both bone marrow cells and peripheral blood monocytes, the
vaccination protocol were limited to only restricted numbers of
injections of lysate-loaded DC per patient (Nestle et al, 1998; Holth
et al, 2002). This may have caused incomplete clinical responses,
which could possibly have been improved by increasing the
number of injections, provided of course enough numbers of DC
were available. Another point that was not thoroughly explored in
these studies considers the actual effector cell type that mediated
the antitumour response. In vivo depletion studies in animal
models indicated that most of this effect was mediated by CD8
þ
cells (Fields et al, 1998; Gatza and Okada, 2002) not discriminating
between T or NK cells expressing this marker. Concerning the
clinical studies, mostly DTH responses to the keyhole limpet
haemocyanin, used as helper antigen, were measured. Ex vivo CTL
responses to certain tumour-associated peptides were weakly
positive and most important it was not checked whether such CTL
could lyse patients’ tumour cells.
In this study, we used for the first time unfractionated peptides
isolated by acid treatment from lysates of HER-2/neu-overexpres-
sing, HLA-A2.1
þ primary ovarian tumour cells to generate in vitro
autologous antitumour CTL. Our data point to the conclusion that
HER-2/neu peptides within ACE from HER-2/neu-overexpressing
ovarian primary tumour cells are immunodominant and that such
preparations can be used in the cellular adoptive immunotherapy
of ovarian cancer.
MATERIALS AND METHODS
Patients
HLA-A2.1
þ patients (n¼5) with histologically confirmed ovarian
cancer (clinical stage III and IV, tumour grade III) were enrolled in
this study. Patients fulfilled the following criteria: Karnofsky
performance status 480%; bilirubin levels o1.7ngdl
 1 and
creatinine levels o2.2ngdl
 1; leucocyte count 43.000ml
 1 and
platelet count 4100000ml
 1. They had not received any anti-
neoplastic therapy during the 3 week preceding the onset of
the study. All patients were apprised of the study, and consents
were obtained consistent with the policies of St Savas Cancer
Hospital.
Preparation of effusion cells
Specimens of peritoneal effusions (1–2l) from patients, collected
during routine aspirations, were spun at 400g for 5min to
sediment cells. Malignant effusion-associated mononuclear cells
(MEAMNC) and tumour cells were isolated from the cell pellet as
previously described (Baxevanis et al, 1994). In agreement with
our previous report (Baxevanis et al, 2000), freshly isolated
MEAMNC consisted mainly of T cells (468% CD3
þ cells) with
almost equal numbers of CD3
þCD8
þ (28–37%) and CD3
þCD4
þ
(32–40%) T cells. A substantial number of monocytes (CD14
þ
cells) was also detected (10–16%). In all cases examined, the
number of MEAMNC isolated from the effusions ranged from 380
to 1.090 10
6 and that of tumour cells from 170 to 650 10
6. Both
MEAMNC (as effectors) and tumour cells (as targets) were utilised
in experiments when viability was 480%.
Monocyte isolation and generation of DC
CD14þ cells were isolated from total MEAMNC using the
Monocyte Isolation Kit (Miltenyi Biotec), comprising a mixture
of CD3, CD7, CD19, CD45RA, CD56, and anti-IgE Abs coupled to
MACS Microbeads according to the manufacturer’s constructions.
Dendritic cells were generated from monocytes in the presence of
800Uml
 1 rGM-CSF (Shering-Plough, Brinny, Innishannon, Ire-
land) and 500Uml
 1 rIL-4 (R&D Systems Europe, Abington, UK),
as described (Baxevanis et al, 2000). The percentage of DC
recorded was 450%, as tested on the expression of CD3
 , CD14
 ,
CD16
 , CD20
 , CD40
 , CD80
 , CD83
  and MHC class IIþ
phenotype. In all cases, the number of DCs generated from
CD14þ cells ranged from 20 to 50 10
6.
Immunophenotyping of tumour cells
HER-2/neu expression was determined on single tumour cells
isolated from the malignant effusions by flow cytometry, using the
PE-conjugated anti-HER-2/neu mAb (clone Neu 24.7; Becton
Dickinson, Mountain View, CA, USA). The expression of HER-2/
neu was qualified by comparing the mean fluorescence intensity
(MFI) of the primary tumour cells with the MFI of tumour cell
lines expressing HER-2/neu at different levels (i.e. HER-2/neu
expression of the MDA-231 cell line is scored as 1 (negligible
expression), of MCF-7 as 2 (intermediate expression) and of SKBR-
3 as 3 (overexpression)) (Sotiropoulou et al, 2003a). In the five
patients examined, HER-2/neu expression on primary tumour cells
from the peritoneal effusions was scored as 3 (Ova-1, Ova-2, Ova-
3) or 0 (Ova-4, Ova-5). All tumour cells expressed HLA-A2.1 (%
range of expression: 55–65) as determined via use of the BB7.2
mAb (kindly provided by Prof H Rammensee at the Department of
Immunology, University of Tuebingen) but were negative for MHC
class II gene products. HLA-A2.1 was the only matching allele
between patients’ primary tumour cells and the human tumour cell
lines used as targets.
Preparation of ACE
This was performed as described (Baxevanis et al, 2000). In brief,
an estimate of 1–2 10
8 tumour cells was washed in HBSS (Life
Technologies, Gaithersburg, MD, USA), followed by homogenisa-
tion in 1ml homogenisation buffer. Eluates from cells were titrated
with 10% trifluoroacetic acid and clarified by two successive
centrifugations at 2500g and 80000g for 30min and 5h,
respectively. Peptides were processed immediately on a Sep-Pak
C18 cartridge (Waters, Bedford, MA, USA) equilibrated prior to
use with 3ml acetonitrile, followed by 3ml deionised water. The
eluate was allowed to flow through the cartridge by gravity, the
column was washed with deionised water and bound material was
finally eluted with 2ml 60% acetonitrile in deionised water and
lyophilised in a Speed-Vac (Heto Lab Equipment, Allerod,
Denmark). Dry product was reconstituted in HBSS and further
processed on a Centricon centrifuge concentrator (Amicon,
Beverly, MA USA) with a cutoff of 10kDa by centrifugation at
2500g at 41C for 2–3h. The filtrate was aliquoted and stored at
 201C.
Peptide synthesis
Peptides were synthesised by the solid-phase method with an
Ecosyn P peptide synthesiser (Eppendorf-Biotronik, Hamburg,
Germany) using the Fmoc strategy and a 4-carboxybenzyl alcohol
resin. Purification was performed by high-performance liquid
chromatography. The purity was 495%. The following HER-2/
neu-derived peptides were synthesised: HER-2/neu (9665), HER-2
(9689), HER-2 (9369), HER-2 (10952), HER-2 (9851) and HER-2 (9402).
These are high binding affinity peptides for HLA-A2.1, eliciting
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1999; Baxevanis et al, 2002). The gp100-derived peptide gp
(9154) and the MART-1/Melan-A-derived peptide Melan (927)
were used as controls. The latter peptides have been demonstrated
to elicit in vitro HLA-A2.1 CTL-restricted activity (Kirkin et al,
1999).
Pulsing with ACE or HER-2/neu-derived peptides
The amount of ACE for pulsing APC (DC or MEAMNC) or target
cells (T2 cells) was determined from its capacity to induce maximal
stabilisation of HLA-A2.1 expression on T2 cells (Fisk et al, 1995).
Based on estimations from our previous report (Baxevanis et al,
2000) and the present one, we pulsed 1 10
6 DC or MEAMNC with
ACE extracted from 5 10
6 primary ovarian tumour cells for
stimulating autologous responder MEAMNC. When T2 cells were
used as targets, loading was performed by incubating 1 10
6 cells
either with ACE from 5 10
6 tumour cells or with the indicated
HER-2/neu synthetic peptides at a 20mgml
 1 final concentration.
Incubations with ACE or peptides were performed overnight in
CO2 incubators.
Generation of ACE-specific CTL lines in vitro
Responder MEAMNC (1 10
6 cellsml
 1) were cultured in 24-well
plates (Costar, Cambridge, MA, USA) with 1 10
5ml
 1 irradiated
(3000rad) autologous DC pulsed with ACE, derived from the
autologous primary tumour cells, in a total volume of 2ml X-VIVO
15 medium supplemented with 1% autologous serum (¼complete
medium), rIL-7 (20ngml) (R&D Systems Europe, Abington, UK)
and 25IUml
 1 rIL-2 (Cetus, Emeryville, CA, USA) in CO2
incubators. After 5–7 days, one-half of the medium was
replenished with fresh medium containing 40ngml
 1 rIL-7 and
50IUml
 1 rIL-2. After an additional 5 days incubation
(¼stimulation phase), recovered responders were washed and
restimulated with thawed autologous irradiated (3000rad) ACE-
pulsed MEAMNC used as APC at a cell ratio of 1:2. Fresh rIL-2
(25IUml
 1) was also added to the medium. After two additional
rounds of restimulation, as above, (¼restimulation phase)
bulk MEAMNC effectors were tested in the in vitro cytotoxicity
assays. Before transfer to SCID mice, the same effectors were
expanded in tissue culture with anti-CD3 mAb (Biosciences; clone
SK7) according to a method previously reported (Riddell et al,
1996).
Cytotoxicity assay
The cytotoxicity assay was performed as previously described
(Baxevanis et al, 1994). Briefly, effector CTL MEAMNC
(1 10
6ml
 1) were placed in 100ml aliquots into wells of 96-well
V-bottomed plates (Costar). As targets, primary tumour cells or
tumour cell lines were labelled with sodium [
51Cr] chromate
(Radiochemical Centre, Amersham, UK; 100–200mCi isotope per
1–2 10
6 target cells) and added to effectors at the indicated E:T
ratios. For peptide recognition, T2 cells were incubated overnight
at 261C together with 20mgml
 1 peptide (or ACE), washed and
then labelled. Incubation was performed for 6h in CO2 incubators.
In some experiments, blocking with an anti-HLA-A2.1 mAb was
performed by preincubating those target cells with 10mgml
 1 of
the BB7.2 mAb. Cytotoxicity values were considered to indicate
significant recognition of a target when the differences between
mean values (from triplicate analyses) for percent lysis of the
particular target (e.g. pulsed T2 cells, primary tumour cells or
transfected tumour cell lines) and unloaded T2 cells or HLA-A2
 
tumour targets were X10% at an E:T ratio of 40:1 and
statistically significant (Po0.05).
Quantitation of cytokines in culture supernatants
An ELISA kit specific for IL-2 was obtained from R&D Systems
Europe. IFN-g was quantitated with an ELISA kit from Endogen
(Boston, MA, USA). Assays were performed according to the
manufacturer’s instructions.
Tumour rejection models
Groups of 10 SCID mice were inoculated s.c. with 5 10
5 cells of
each tumour cell line in 0.5ml PBS. Injections with ACE-specific
CTLs (2 10
7 cells in 0.5ml PBS) were administered intraper-
itoneally (i.p.) at the time point when tumour was palpable
(ca. 10–16 days after inoculation of mice with the tumour cell
lines). Tumour size was monitored regularly every 4 days and was
expressed as the product of the perpendicular diameters of
individual tumours. Each animal experiment was repeated at least
twice. The observation was terminated with the euthanasia of mice
when the tumour mass grew up to 200–250mm
2 in diameter. A
nonparametric Wilcoxon rank test was used in the statistical
analysis of the size of the tumour in individual groups. The
difference was considered statistically significant when Po0.05.
RESULTS
ACE-induced CTL with cytotoxic activity against HER-2/
neuþ HLA-A2.1
þ tumour cell lines and primary
autologous tumour cells
Acid cell extracts prepared from HER-2/neu-overexpressing, HLA-
A2.1
þ primary tumour cells were tested for their ability to elicit
specific CTL from autologous MEAMNC. These tumour cells were
isolated from peritoneal effusions of three patients with ovarian
cancer (designated Ova-1, Ova-2, Ova-3). Dendritic cells differ-
entiated from monocytes within the MEAMNC population were
used, pulsed with ACE, as APC. After a stimulation phase in the
presence of IL-2 and IL-7, which was followed by three
restimulations with autologous MEAMNC pulsed with ACE, as
APC, the bulk effector MEAMNC population consisted of both
CD8
þ and CD4
þ T cells (% mean7s.d. in the three bulk cultures:
54710 and 43710, respectively). Although total MEAMNC
effectors were utilised in the cytotoxicity experiments (see below),
for simplicity reasons these are referred to as CTL. Bulk CLT
cultures efficiently lysed T2 targets pulsed with ACE derived from
the autologous ovarian primary tumour cells (Figure 1, left panel).
The same cultures were also tested for CTL activity against various
targets including the autologous ovarian primary tumour cells and
HLA-A2.1
þ, HER-2/neu
þ tumour cell lines. As shown in Figure 1,
bulk CTL activity induced by ACE from Ova-1, Ova-2 and Ova-3
primary tumour cells could be demonstrated against the respective
autologous tumour cells (Figure 1, left panel) as well as against the
HER-2/neu
þ ovarian cell line SKOV3 transfected to express HLA-
A2.1 (SKOV3.A2; provided by Dr C-G Ioannides, Department of
Gynecologic and Oncology and Immunology, university of Texas,
MD Anderson Cancer Center) and the HER-2/neu
þ HLA-A2.1
þ
breast cancer cell line MCF-7 (Figure 1, right panel). In contrast,
the same effectors failed to lyse the HER-2/neu-overexpressing but
HLA-A2
  parental SKOV3 and breast cancer cell line SKBR3
(HLA-A2.1 was the only matching allele between the primary
ovarian tumours and these tumour cell lines) or the HER-2/neu
 
mouse fibrosarcoma cell line MC57X(H-2
b). Cytotoxicity was
HLA-A2.1-restricted since it was to a great extent inhibited in the
presence of BB7.2 mAb (% range of inhibition against the
autologous tumour and MCF-7 targets: 56–77 at a cell ratio of
40:1) (Figure 1). The finding that our ACE-induced CTL
specifically lysed HER-2/neu
þ HLA-A2.1
þ tumour cells demon-
strates their ability to recognise naturally processed peptides
Tumour lysate-induced antitumour effectors
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of HLA-A2.1 molecules.
In contrast to ACE prepared from the Ova-1, Ova-2 and Ova-3
tumours, ACE derived from the HER-2/neu
  HLA-A2.1
þ Ova-4
and Ova-5 primary tumours induced only a modest CTL activity
against the autologous primary tumour targets or the HER-2/neu
þ
HLA-A2.1
þ SKOV3.A2 and MCF-7 tumour lines (Figure 1). Such
cytotoxic responses were apparently directed against ACE peptides
other than those derived from HER-2/neu, which were also
presented in the context of HLA-A2.1 molecules, since (i) there
was significant inhibition of the response in the presence of BB7.2
mAb (range of % inhibition for the autologous tumours,
SKOV3.A2 and MCF-7 targets: 54–79); (ii) only marginal killing
was observed against the HLA-A2.1
  SKOV3 and SKBR3 cell lines
(Figure 1, right panel) and (iii) significant levels of cytotoxicity
(55% and 48%) were observed when ACE-pulsed T2 cells were
used as targets (Figure 1, left panel).
The relatively high percentages of cytotoxicity against the ACE-
pulsed T2 targets vs the weak lysis of the autologous tumour
targets as well as the SKOV3.A2 and MCF-7 cell targets suggests
that the peptides within ACE prepared from HER-2/neu
  ovarian
primary tumour cells Ova-4 and Ova-5 are to a great extent not
naturally expressed on the surface of the tumours and therefore
cannot be considered as strongly immunogenic. The percentages
of CD4
þ T cells within the bulk MEAMNC population by culture
termination were at relatively equal levels (33 and 47%), with those
in bulk cultures sensitised by ACE from the HER-2/neu
þ primary
tumours Ova-1, Ova-2 and Ova-3, thus excluding the possibility
that low numbers of CD4
þ T cells, apparently providing
insufficient help for CD8
þ CTL, could account for the low
       Ova-5
       Ova-1
       Ova-2
       Ova-3
       Ova-4
E/T ratio 
%
 
C
y
t
o
t
o
x
i
c
i
t
y
0
10
20
30
40
50
60
70
20 10 5
T2 +ACE T2 
AuTu AuTu +A2
MC57X
0
10
20
30
40
50
60
20 10 5
SKOV3.A2 MCF-7
SKBR3 SKOV3
MCF-7 +A2   
0
5
10
15
20
25
30
35
40
45
20 10 5
0
10
20
30
40
20 10 5
0
10
20
30
40
50
20 10 5
0
10
20
30
40
50
20 10 5
0
10
20
30
40
50
60
20 10 5
0
10
20
30
40
50
60
20 10 5
0
10
20
30
40
50
60
20 10 5
0
10
20
30
40
50
60
20 10 5
Figure 1 Cytotoxic responses mediated by MEAMNC bulk CTL after in vitro culture with ACE derived from HLA-A2.1 primary ovarian tumour cells
overexpressing HER-2/neu (Ova-1, Ova-2 and Ova-3) or being HER-2/neu
  (Ova-4 and Ova-5). Cytotoxicity was tested against various targets also
including the autologous primary tumour cells (AuTu) from which the ACE was extracted. In some cases, anti-HLA-A2.1 mAb (aA2) was added throughout
the cytotoxicity assay. One experiment of three performed is shown. Mean values7s.d. from triplicate cultures are shown.
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or the tumour cell lines.
HER-2/neu peptides recognised by ACE-induced MEAMNC
bulk cultures
To more precisely delineate the immunodominant role of HER-2/
neu-derived peptides within the ACE from HER-2/neu-over-
expressing ovarian primary tumour cells, we attempted to link
the cytotoxic activity mediated by the ACE-induced CTL against
the HER-2/neu
þ HLA-A2.1
þ tumour targets with their ability to
lyse T2 cells pulsed with HER-2/neu synthetic peptides known to
represent HLA-A2.1-restricted CTL epitopes. As presented in
Table 1, effectors induced with ACE from Ova-1 tumours
recognised peptides HER-2 (9851), HER-2 (9435), HER-2 (9665)
and HER-2 (9369). Peptides HER-2 (9435) and HER-2 (9369) were
also recognised by CTL bulk cultures induced with ACE from Ova-
2 and Ova-3 primary tumours. The same effectors lysed T2 cells
pulsed with HER-2 (9689) but not the same targets pulsed with
peptides HER-2 (9851) or HER-2 (9665). None of the effectors
recognised HER-2 (10952) and HER-2 (9402) or control peptides
Melan A (927) and gp (9154). In addition, there was no reactivity by
any of the three CTL cultures against. As expected, CTL bulk
cultures sensitised with ACE from the HER-2/neu
  Ova-4 and Ova-
5 tumours did not recognise any of the HER-2/neu peptides tested.
Cytokine production by the bulk MEAMNC effectors
Parallel experiments were set up to quantitate cytokine production
by the same ACE-induced MEAMNC effectors used in the
cytotoxicity experiments. Cytokine levels were measured in culture
supernantants by culture termination (i.e. after the third
restimulation). With the use of commercially available ELISA kits,
both IFN-g and TNF-a were detected at varying concentrations.
The data from Figure 2 clearly show that IFN-g and TNF-a levels
produced by the MEAMNC bulk population sensitised with ACE
from the HER-2/neu
  Ova-4 and Ova-5 primary tumours (in
ngml
 1: 20.4 and 7.2 for IFN-g; 2.9 and 5.7 for TNF-a, respectively)
were almost within the range of concentrations quantitated in the
supernatants of MEAMNC cultures stimulated by ACE from the
HER-2/neu
þ Ova-1, Ova-2 and Ova-3 primary tumours (range:
7.6–17.3 for IFN-g and 1.3–10.5 for TNF-a). Only marginal levels
of IL-4 could be detected in all five cases (o0.1ngml
 1; data not
shown). These data demonstrated that the culture conditions used
favour the production of Th1 cytokines supporting antitumour
immunity. In addition, they support the idea that the low
cytotoxicity induced by ACE preparations from Ova-4 and Ova-5
HER-2/neu
  primary tumours should rather be attributed to an
inadequate recognition of tumour targets than to qualitative
differences in cytokine secretion profiles by the MEAMNC
effectors.
ACE-induced MEAMNC effectors when adoptively
transferred mediate antitumour responses in xenografted
SCID mice
Next, we attempted to determine whether our ACE-induced CTL
effectors could exert antitumour effects in vivo by protecting SCID
mice against the growth of the human tumour cell lines, which
were previously used as targets in the in vitro cytotoxicity
experiments. Cytotoxic T lymphocytes effectors after the restimu-
lation phase were expanded in the presence of anti-CD3 mAb and
rIL-2 and transferred at 2 10
7 cells per mouse to SCID mice with
palpable subcutaneous tumours (these mice had been inoculated
10–16 days before with the tumour cell lines). As shown in
Figure 3A, these tumour lines were growing relatively fast and
formed large tumours (4200mm
2 area) within 30–44 days in
untreated animals. Such vigorous tumour growth was not
restrained when mice were treated with a human CTL line specific
for the HLA-A2.1-restricted epitope gp (9154) of the melanoma-
associated gp100 protein (Figure 3B). This line was capable of
lysing human melanoma lines expressing both HLA-A2.1 and
gp100 (data not shown). Transfer of the HLA-A2.1-restricted and
HER-2/neu-recognising MEAMNC effectors sensitised with ACE
from Ova-1 (Figure 3C), Ova-2 (Figure 3D) or Ova-3 (Figure 3E)
induced a significant delay in the growth of SKOV3.A2 and MCF-7
tumour lines (growth of both tumours reached an area 4200mm
2
104–138 days after inoculation; Po0.01 compared to nontreated
mice or mice treated with the gp (9154)-specific CTL). The same
effectors remained without any effect when SCID mice were
inoculated with the HER-2/neu
þ HLA-A2.1
  tumour lines SKBR3
or SKOV3 or with the murine MC57X fibrosarcoma (Figure 3C–E),
demonstrating the specificity of the in vivo responses. In
Table 1 ACE-induced CTL from patients with ovarian cancer recognise HER-2/neu peptides
HER-2/neu peptides
Effectors
a Melan (927)G p ( 9 154)( 9 851) (10952)( 9 689)( 9 402)( 9 435)( 9 665)( 9 369)
Ova-1 7.0
b 8.5 21.5
c 7.6 11.3 8.8 47.6 38.7 39.5
Ova-2 2.5 6.3 8.5 7.2 41.7 12.1 52.7 10.3 35.9
Ova-3 9.0 5.5 6.9 3.9 25.6 3.9 52.8 6.7 30.6
Ova-4 6.5 7.2 10.2 8.3 7.2 10.5 9.3 7.5 3.9
Ova-5 10.2 3.2 5.6 2.5 5.7 9.6 11.2 6.8 7.5
aMEAMNC sensitised in vitro against ACE from autologous HER-2/neu-overexpressing primary tumour cells (Ova-1–Ova-5) were tested as effectors for cytotoxicity against T2
cells pulsed with the indicated HER-2/neu peptides. Effector to target ratio¼40:1.
bIndicates mean % cytotoxicity values from triplicate cultures. The s.d. (not shown) was always
less then 15% of the mean values.
cStatistically significant cytotoxic responses (Po0.01) over background responses (i.e. cytotoxicity against unpulsed T2 targets) and over
cytotoxicity against control Melan (927) and gp (9154) peptides. Bold values indicate significance in comparison with control values.
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Figure 2 Cytokine production by the MEAMNC bulk CTL. Cytokine
determinations were performed in parallel with the cytotoxicity assays.
Cytokines were quantitated in culture supernatants after the end of the
restimulation phase. Ova-1 through Ova-5 indicates the primary ovarian
tumour cells which were used as source for ACE preparation. Mean
values7s.d. from three parallel cultures (from the same MEAMNC donor)
are shown.
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sagreement with the in vitro results (Figure 1), transfer of
MEAMNC effectors induced in vitro with ACE from the HER-2/
neu
  primary tumours did not exert any significant antitumour
effects in vivo (Figure 3F and G).
DISCUSSION
In this study, we demonstrate for the first time the capacity of ACE
from HER-2/neu-overexpressing primary ovarian tumour cells to
induce in vitro autologous CTL from MEAMNC with the ability to
exert in vivo antitumour effects against HER-2/neu
þ human
tumour cell lines. Such CTL recognised peptides within ACE which
were naturally processed and expressed on the surface of tumour
cells in the context of the HLA-A2.1 allele. This was indicated by
the following findings: first, ACE peptides induced stabilisation of
HLA-A2.1 molecules on T2 cells and such ACE-pulsed T2 cells
were efficiently lysed by our ACE-induced CTL effectors; second,
HER-2/neu
þ, HLA-A2.1
þ primary tumour cells as well as human
tumour cell lines of breast and ovarian origin were lysed in an
HLA-A2.1-restricted fashion since the cytotoxicity was to a great
extent abrogated in the presence of the mAb BB7.2, and third,
HER-2/neu-overexpressing but HLA-A2.1
  human cell lines were
not lysed.
By pulsing T2 cells with synthetic HER-2/neu CTL peptides, we
could identify immunodominant nanomers that were recognised
by our ACE-induced bulk CTL. These included peptides HER-2
(9369), HER-2 (9435) (both recognised by bulk CTL induced by ACE
preparations from Ova-1, Ova-2 and Ova-3 primary HER-2/neu-
overexpressing tumours), peptide HER-2 (9689), which may be
recognised by Ova-2 and Ova-3 induced CTL, and peptides HER-2
(9851) and HER-2 (9665), which were recognised by one of the three
bulk CTL. These HER-2/neu peptides have been demonstrated to
bind to HLA-A2.1 molecules with high affinities (Fisk et al 1995;
Rongcun et al, 1999), thereby eliciting CTL activity among
tumour-associated lymphocytes in patients with breast and
ovarian cancer (Fisk et al, 1995; Rongcun et al, 1999; Baxevanis
et al, 2002). Moreover, we have recently demonstrated the capacity
of these peptides to sensitise CTL for lysing their autologous
tumour cells in patients with prostate, lung and colorectal cancer
(Sotiropoulou et al, 2003a,b). Thus, our data demonstrate the
utility of ACE preparations as polyepitope carriers. Such carriers
besides the HER-2/neu peptides identified, most likely contain
others which remain to be identified by screening the entire HER-
2/neu protein for sequences with HLA-A2.1-binding motifs,
followed by peptide synthesis, loading onto T2 targets and testing
in cytotoxicity assays with ACE-induced CTL effectors.
Although HLA-A2.1 is the most popular allele for presenting
HER-2/neu CTL epitopes, there are also other MHC class I alleles
functioning as restriction elements for HER-2/neu peptide
presentations (Kiessling et al, 2002). Accordingly, recognition of
the HER-2/neu
þ, HLA-A2.1
  SKOV3 or SKBR3 cell lines by our
ACE-induced bulk CTL effectors could also be accomplished
through HLA- class I alleles other than HLA-A2.1. However,
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Figure 3 Adoptive transfer of MEAMNC bulk CTL induced by ACE from HER-2/neu-overexpressing HLA-A2.1
þ primary ovarian tumour cells (Ova-1,
Ova-2 and Ova-3) suppress the growth of human HER-2/neu
þ, HLA-A2.1
þ tumour lines in SCID mice (C, D and E, respectively). (F, G) Results with
MEAMNC bulk CTL induced by ACE from HER-2/neu
  HLA-A2.1þ primary Ova-4 and Ova-5 tumour cells, respectively. Cytotoxic T lymphocytes were
i.p. injected at 2 10
7 cells per injection (one injection was given per mouse) in SCID mice with s.c. growing tumours which were induced upon inoculation,
10–16 days before, with the indicated human tumour lines or the mouse fibrosarcoma MC57X. Control CTL (B) consisted of CTL specific for the
melanoma gp (9154) peptide. (A) Growth of tumour lines in untreated SCID mice. Cytotoxic T lymphocytes used for adoptive transfer were expanded (as
described in Materials and Methods) from the same cultures shown in the previous figures and presented in Table 1. One experiment out of two with similar
results is shown. In rapidly growing tumours, the s.d. was too low (i.e. o5% of the means) and thus omitted.
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saccording to the serotyping, only the HLA-A2.1 subtype was
shared between the primary HER-2/neu-overexpressing Ova-1,
Ova-2 and Ova-3 tumours (which served as source for the ACE
preparation) and the SKOV3 or SKBR3 tumour cell lines and
therefore only HER-2/neu peptide-specific and HLA-A2.1-re-
stricted CTL clones would have a chance to recognise them. Of
course, recognition could also have been established through CTL
clones specific for HLA-A2.1-restricted peptides other than those
derived from the HER-2/neu oncoprotein. Although this is quite
likely, still the contribution of such clones would not add much to
overall killing of the HLA-A2.1
þ tumour targets. This hypothesis
is based on our findings demonstrating that CTL induced by ACE
from the Ova-4 and Ova-5 HLA-A2.1
þ but HER-2/neu
  primary
tumours only weakly lysed their autologous tumour targets (i.e. the
Ova-4 and Ova-5 primary tumours) as well as the HLA-A2.1
þ and
HER-2/neu
þ SKOV3.A2 and MCF-7 tumour cell lines. Thus, it
seems possible that peptides within ACE from the HER-2/neu
 
primary ovarian tumours are weakly immunogenic most likely due
to inefficient expression and presentation on the tumour cell
surface. This is supported by the findings that both the Ova-4- and
the Ova-5-ACE induced CTL, although exerting weak cytotoxic
activity against the HLA-A2.1
þ HER-2/neu
  autologous primary
tumours and against the HLA-A2.1
þ HER-2/neu
þ tumour cell
lines, still were capable of (i) efficiently lysing T2 targets pulsed
with the same ACE (i.e. those prepared from Ova-4 and Ova-5
primary tumours), and (ii) producing substantial amounts of IFN-
g and TNF-a after the restimulation phase. Both parameters were
comparable to those of CTL induced by ACE from the HER-2/neu-
overexpressing Ova-1, Ova-2 and Ova-3 primary tumours.
SCID mice were protected against inoculation with HER-2/
neu
þ, HLA-A2.1
þ human tumour cell lines when bulk CTL
specific for ACE prepared from the HER-2/neu-overexpressing
primary ovarian tumours were adoptively transferred. Indepen-
dently of the HER-2/neu peptides recognised, Ova-1CTL (recog-
nising HER-2 (9851), HER-2 (9435), HER-2 (9665) and HER-2 (9369)),
Ova-2CTL (recognising HER-2 (9689), HER-2 (9435) and HER-2
(9369)) and Ova-3CTL (recognising HER-2 (9689), HER-2 (9435) and
HER-2 (9369)) induced similar levels of protection demonstrating
the immunodominance of these HER-2/neu epitopes, but not
excluding, however, the possibility that also CTL clones specific for
other HER-2/neu epitopes may be included in these bulk CTL
populations.
There are several models described so far in the literature
utilising different vehicles for vaccination studies with polyepitope
constructs. These include attenuated virus vectors (Toes et al,
1997; Schneider et al, 1998) naked DNA (Thomson et al, 1998) or
transfected DC (Condon et al, 1996). Acid cell extracts prepara-
tions from primary tumour cells may be advantageous over such
polyepitope vaccines not solely due to the fact that these
apparently contain a plethora of CTL epitopes, but also due to
the simplicity of the method used for their preparation and
administration. In addition, ACE derived from primary tumours
may contain T helper epitopes as well (Baxevanis et al, 2000),
which will contribute to the enhancement of CTL-mediated
antitumour responses. In contrast to other reports utilising
tumour cell lysates or unfractionated tumour peptides in active
immunisation studies (Nair et al, 1997; Fields et al, 1998; Gatza and
Okada, 2002; Schnurr et al, 2002; Wen et al, 2002; Gad et al, 2003;
Graner et al, 2003; Vegh and Mazumder, 2003), our data emphasise
the role of such preparations in the cellular adoptive immunother-
apy of cancer by sensitising in vitro the effector CTL population.
Collectively, the studies presented herein provide evidence that
pooled peptides from HER-2/neu-overexpressing ovarian tumours
can be utilised in cellular adoptive immunotherapy of patients with
HER-2/neu
þ ovarian cancer. They also imply that vaccination
with such multiepitope preparations may allow enhanced efficacy
in the clinical treatment of ovarian cancer. Moreover, the
identification of immunodominant HER-2/neu peptides within
these unfractionated peptide extracts may help in the collection of
peptides to be included in multipeptide vaccines.
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